

Morocco

COUNTRY GENERAL INFORMATION

Total population:	35 581 257
Gender F/M (%):	50.4 / 49.6
Population, age group <15 / ≥ 15 years (%):	28 / 73
Life expectancy at birth (F/M, years):	74 / 71
GDP (PPP int \$):	8261
Income status:	Lower middle income
Number of 2 nd sub-national administrative level divisions, name:	75, Province



EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	107	2035	4748	N/A
Number of relapses: ¹	No data	4	1	N/A
Total number of cases:	107	2044^A	4763^B	N/A
Imported cases (#, %):	1, 1%	No data	No data	No data
Gender distribution (% F):	45	55	50	N/A
Age group distribution (% <5 / 5-14 / >14):	75 / 13 / 12	35 / 31 / 34	29 / 65 / 6	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.06	1.09	16.45	N/A
Number of endemic 2 nd sub-national administrative level divisions:	36	38	9	N/A
Population at risk (% # at risk / total population): ²	49% 17 314 725/ 35 581 257	53% 18 709 882/ 35 581 257	8% 2 894 920/ 35 581 257	N/A
Was there any outbreak?	No	Yes	Yes	N/A
Number of new foci: ³	No data	1	3	N/A



Monthly distribution of new cases (January-December)

2017	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	7	13	26	7	8	5	9	4	6	9	7	5
ACL	234	273	333	314	180	99	119	82	87	92	123	108
ZCL	847	193	87	122	69	36	94	70	164	334	945	1802

N/A not applicable; VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis



Number of new cases and incidence rate/10 000 at the national level from 2002 to 2017



^AIncludes 5 cases classified as "unspecified"


^BIncludes 14 cases classified as "unspecified"

¹Relapse in this country is defined for VL as: "non response 3 weeks after start of treatment" and for CL as: "reappearance of lesion 6 weeks after start of treatment"

²Defined as "Number of people living in 3rd sub-national administrative level endemic areas"

³Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever"

Disease distribution of new VL, ACL and ZCL cases at Province level per 10 000 population (2017)



CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1997
Type of surveillance (CL / VL):	Vertical / Vertical
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Pyrethroid
Year latest national guidelines (CL / VL):	2010 / 2010
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	Yes / Yes
Is there a reservoir host control programme?	Yes
Number of leishmaniasis health facilities (CL / VL):	No data / No data

DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	0	250 236	374 912	N/A
Number of people screened passively for:	107	2888	2951	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	100% (107/107)	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	100% (107/107)	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	35% (37/107)	77% (1575/2040)	8% (397/4762)	N/A
Proportion of positive slides (% , # slides + / total slides):	97% (37/38)	55% (1575/2888)	13% (397/2951)	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	9% (10/107)	23% (465/2040)	92% (4365/4762)	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Meglumine antimoniate

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	100% (107/107)	No data	No data
Initial cure rate (% , # cases initially cured / new cases):	100% (107/107)	100% (2035/2035)	100% (4748/4748)
Failure rate (% , # cases with treatment failure / new cases): ⁴	No data	0% (6/2035)	No data
Case fatality rate (% , # cases who died / new cases):	1% (1/107)	No data	No data

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

⁴Failure in this country is defined for VL as: "Persistence of symptoms during the treatment period" and for CL as: "Bad evolution of lesion after 2 weeks of treatment or persistence of lesion after 6 weeks of treatment"